ALXOALX Oncology Inc.Running, no new patients
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma
14Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Mar 2025, none posted yet
Counts until it's fixed
- +3.9
2 insiders sold shares within a month
Since Aug 17, 2026 · was worth 10, fading over time
Worry score14
Score over time
- Stage
- Phase 2
- Patients
- 172 (final count)
- Started
- May 10, 2021
- Main results expected
- Mar 3, 2025
- Fully finished
- Jun 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate per RECIST 1.1
Measured over: Last randomized patient reaching at least 24 weeks of follow-up
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-03-03, no fading
- insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04675333 · record last updated 2025-08-03 · checked 2026-11-09 15:47 UTC